Client Alerts & Insights
Insulet Corp. May Have to Choose Between $452 Million Jury Award or Permanently Blocking Competitor From Utilizing Its Trade Secrets
March 17, 2025
Authored By:
After receiving a jury verdict awarding $452 million in damages against a rival company for misappropriation of trade secrets, the prevailing party, Insulet Corp., may have to choose between portions of the damages award or permanently blocking the rival company from continuing to sell its products based on the stolen technology.
In August 2023, Insulet, a medical device company, sued a rival company, EOFlow, for misappropriation of Insulet’s trade secrets. On December 3, 2024, after a four-week trial in the District of Massachusetts, the jury returned a verdict in favor of Insulet finding that EOFlow misappropriated four of Insulet’s trade secrets in creating its insulin patch pump. The jury awarded Insulet $170 million in compensatory damages and $282 million in exemplary or punitive damages, totaling $452 million.
Shortly after Insulet’s victory, Insulet filed a motion to permanently stop EOFlow from selling the insulin patch pump that it created based on Insulet’s proprietary technology. EOFlow challenged Insulet’s request arguing that, if granted, the injunction would overlap with the damages awarded by the jury which, in part, compensate Insulet for EOFlow’s future profits from its insulin patch product.
Recognizing that a company should not be able to continue to use and profit from stolen trade secrets, Chief U.S. District Judge F. Dennis Saylor IV concluded that some type of injunction would be required. Judge Saylor also concluded that Insulet could not receive both an injunction and keep the full jury award since the relief would overlap. Instead, Judge Saylor suggested Insulet choose whether it wants injunctive relief or the portion of the jury award that captures “unrealized value” from the trade secrets. With Judge Saylor’s proposal as one option, he directed the parties to file new briefs with proposals on how to reconcile the competing interests.
The outcome of Insulet and EOFlow’s post-trial remedy dispute could impact the interplay between monetary and injunctive relief in ongoing and future trade secret actions. Benesch attorneys will be watching the outcome of this dispute closely. If you have any questions, please reach out to:
Katie Burnett at kburnett@beneschlaw.com or 312.624.6357.
Samantha Marchand at smarchand@beneschlaw.com or 312.212.4938.
Latest News
2026 Proposed Amendments to the Federal Sentencing Guidelines—Key Changes for Economic Crimes
The United States Sentencing Commission (the “Commission”) published its proposed 2026 amendments to the Federal Sentencing Guidelines in two phases—in December 2025 and January 2026—with a period for public comment through February 10, 2026, and March 18, 2026, respectively.
Dance Like No One is Watching, Text Like Your Words Will Be Published on the Front Page: The Importance of Internal Compliance with FINRA and Text Message Production
Earlier this month, Benjamin Edwards, a broker-dealer firm, agreed to a censure and to pay a $750,000 fine for failing to properly supervise and preserve its employees’ business-related text messages.
Increased Medicare Enforcement Forthcoming? Minnesota Legislature, Attorney General Propose Expanded Charging Authority, Higher Penalties
On February 25, 2026, Minnesota Attorney General Keith Ellison, together with bipartisan legislative sponsors, introduced the 2026 Medical Assistance Protection Act (“MAP”), a sweeping proposal that would materially expand the state’s Medicaid fraud enforcement framework.
CMS Issues a Nationwide Moratorium on New Medicare Enrollment of Some DMEPOS Suppliers
CMS has imposed a six‑month nationwide moratorium beginning February 27, 2026, that blocks new Medicare enrollments for certain DMEPOS suppliers as part of its CRUSH initiative.